PEREGRINE ANNOUNCES DEFENSE DEPARTMENT GRANT TO STUDY TARVACIN PLATFORM FOR PROSTATE CANCER

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - News), a biopharmaceutical company with a portfolio of innovative, clinical-stage product candidates for viral diseases and cancer, today announced the U.S. Department of Defense Prostate Cancer Research Program has awarded a grant totaling $582,988 to the University of Texas Southwestern Medical Center at Dallas to study the use of vascular targeting antibodies in combination with chemotherapy agents for the treatment of prostate cancer.
Yahoo News